CSIMarket
 
Beam Therapeutics Inc   (BEAM)
Other Ticker:  
 
 
Price: $35.4100 $0.80 2.311%
Day's High: $35.45 Week Perf: -3.17 %
Day's Low: $ 33.50 30 Day Perf: 13.17 %
Volume (M): 3,023 52 Wk High: $ 49.50
Volume (M$): $ 107,030 52 Wk Avg: $28.67
Open: $34.04 52 Wk Low: $16.95



 Market Capitalization (Millions $) 2,798
 Shares Outstanding (Millions) 79
 Employees -
 Revenues (TTM) (Millions $) 82
 Net Income (TTM) (Millions $) -314
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 38

Beam Therapeutics Inc


   Company Address: 238 Main Street Cambridge 2142 MA
   Company Phone Number: 327-8775   Stock Exchange / Ticker: NASDAQ BEAM
   


Customers recorded net loss Customers recorded net loss



• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FBIN   -1.52%    
MAS   -2.22%    
MO        3.39% 
NWL      0% 
SEB        0.3% 
SWK   -3.57%    
• View Complete Report
   



Beam Therapeutics Inc

Beam Therapeutics Inc Reports Disturbing $-1.22 Per Share Deficit During July-September 2023 Financial Period


Date:
Beam Therapeutics Inc, a leading company in the Biotechnology & Pharmaceuticals sector, has emerged as a beacon of hope amidst a challenging market environment. The company's financial performance for the July to September 30, 2023 financial interval demonstrates its ability to overcome obstacles and navigate through unprecedented circumstances.
During this period, Beam reported a loss of $-1.22 per share, marking an improvement from the $-1.56 loss per share recorded in the previous year. Additionally, the company's revenue for the quarter experienced significant growth, advancing by 8.823% to $17.19 million, compared to $15.80 million in the corresponding reporting season a year prior.

Beam Therapeutics Inc

Beam Therapeutics Inc Still Hustling for Profitability Despite Revenue Boost in Q2 2023



In the most recent fiscal period, Beam Therapeutics Inc, a prominent Biotechnology & Pharmaceuticals company, reported a noteworthy 20.802% surge in revenue, reaching $20.12 million. This marked a significant improvement from the corresponding reporting season a year prior. However, an alarming development revealed that the company's Diminishing Returns expanded at $-1.08 per share. This unexpected contrast has caught the attention of industry observers, as Beam Therapeutics Inc stands out as a rare success story in a Biotechnology & Pharmaceuticals sector that witnessed a substantial -15.53% decline in top-line revenue. This article will explore the implications of these results and their potential impact on the company's future prospects.
Revenue Growth Amidst Industry Decline:
The remarkable revenue growth of 20.802% exhibited by Beam Therapeutics Inc has placed the company in a favorable position compared to its industry counterparts. While the rest of the Biotechnology & Pharmaceuticals sector experienced a significant decline in top-line revenue, Beam Therapeutics Inc managed to buck the trend, reinforcing its prominence as a rising star. This surge in revenue has undoubtedly boosted investor confidence and positioned the company as a standout performer within the industry.

Beam Therapeutics Inc

Beam Therapeutics Inc Surges in Q1 2023 Earnings with Impressive Growth

Beam Therapeutics Inc Reports Cumulative Net Loss of $-316 Million and Negative Return on Assets in Q1 2023
In the first quarter of 2023, Beam Therapeutics Inc recorded a cumulative net loss of $-316 million, resulting in a negative return on assets (ROA) of -23.25%. This places the company below the overall ROA ranking, with 263 other healthcare sector companies having a higher return on assets.
However, the company's overall ranking has improved in the first quarter, advancing to 2437 from the total ROA ranking of 4000 in the fourth quarter of 2022.






 

Beam Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com